Table 1 Baseline characteristics of C3GN and C3 Control patients
Category | C3GN (n = 10) | C3 Controls (n = 21) | p value |
|---|---|---|---|
Gender (% Male) | 50 (n = 5) | 33(n = 7) | 0.4 |
Age at diagnosis (years) | 57 (41–61) | 55 (35–65) | 0.9 |
SBP (mmHg) | 140 (122–160) | 145 (128–154) | 0.9 |
DBP (mmHg) | 83 (68–89) | 80 (70–87) | 0.7 |
Caucasian (%) | 60 (n = 6) | 85 (n = 18) | 0.08 |
Asian (%) | 0 | 10 (n = 2) | 0.2 |
Aboriginal (%) | 0 | 0 | – |
Torres Strait Islander (%) | 10 (n = 1) | 5 (n = 1) | 0.04 |
Hispanic (%) | 0 | 5 | 0.3 |
Black (%) | 0 | 0 | – |
AKI (%) | 60 (n = 6) | 57 (n = 12) | 0.9 |
AKI needing acute HD (%) | 30 (n = 30) | 14 (n = 3) | 0.3 |
Nephrotic syndrome (%) | 30 (n = 30) | 10 (n = 2) | 0.3 |
Haematuria (%) | 100 (n = 10) | 80 (n = 17) | 0.3 |
uPCR at diagnosis (mg/mmol) | 300 (106–947) | 154 (55–573) | 0.7 |
Creatinine at diagnosis (umol/L) | 253 (103–333) | 127 (105–182) | 0.01 |
Complement levels (C3) | 0.91 (0.56–1.04) | 1.15 (0.93–1.39) | 0.4 |
Low Complement levels (%) | 20 | 19 | 1 |
ANA titre (dilution) | 80 (80–329) | 80 (0–200) | 0.6 |
ANCA (% positive) | 0 | 20 | 0.2 |
C3Nef/CFH/CFb antibody (%) | 0 (n = 0/2) | 0 not tested | – |
Significant light chain ratio (% positive) | 0 (n = 0/4) | 0 (n = 0/7) | – |
ASOT titre (+) > 200 IU (%) | 0 (n = 0/2) | 50 (n = 1/2) | 0.2 |